The Food and Drug Law Institute (FDLI) will present academic scholarship at the 2023 Food and Drug Law Journal Symposium, an event featuring scholarly experts and seasoned practitioners who will delve into the profound implications of both recent and upcoming federal court decisions for the U.S. Food and Drug Administration (FDA). The Symposium aims to explore the evolving legal landscape and its intricate interplay with the agency’s regulatory authority. By examining pivotal cases brought before the federal bench, including those that ultimately may reach the U.S. Supreme Court, Symposium participants will shed light on the potentially far-reaching repercussions for FDA’s operations.
The Call for Abstracts closed on July 24, 2023. Following the Symposium on November 8, 2023, finalized papers will be considered for publication in a dedicated issue of the Food and Drug Law Journal.
Call for Abstracts
The Call for Abstracts is now closed. A preliminary agenda will be announced in September.
Submission Timeline
- Wednesday, October 18, 2023: Draft papers are due
- Wednesday, November 8, 2023: FDLJ Symposium
The Food and Drug Law Journal (FDLJ) is the publication sponsor for this Symposium and reserves a right of first refusal to publish accepted papers, subject to the editorial review process. All final papers should be under 25,000 words in length, double-spaced, and in Times New Roman font. FDLJ requires footnotes that conform with the 21st edition of The Bluebook: A Uniform System of Citation. Additional author guidelines are available here. Questions regarding submission requirements may be directed to [email protected].
Please contact Paige Samson with any questions about the Symposium.
Planning Committee
Marie Boyd, University of South Carolina School of Law
Christine P. Bump, Penn Avenue Law & Policy
Michelle Divelbiss, Covington & Burling LLP
Bridget C.E. Dooling, The Ohio State University Moritz College of Law
Lewis A. Grossman, American University
Emily C. Helms Williams, FDA – OC
John F. Johnson III, Shook, Hardy & Bacon LLP
Peter V. Lindsay, Paul Hastings, LLP
Markham C. Luke, FDA – CDER
Catherine A. Melfi, Omeros Corporation
Alan G. Minsk, Arnall Golden Gregory LLP
James O’Reilly, University of Cincinnati
Daniel Orr, Thomson Reuters Inc.
Shy Shorer, NIH, NCI, CCR
